Article
Biochemistry & Molecular Biology
Chao Lin, Ying Kong, Furong Wang, Rong Rong, Xiangping Li, Rensong Xiao, Ziqi Wu, Qiuyan Zhang, Lin Wang
Summary: In this study, a series of new DPP-4 inhibitors were designed and synthesized, and compound 6c showed promising potential for the treatment of T2DM with better pharmacokinetic profile and efficacy.
BIOORGANIC CHEMISTRY
(2022)
Article
Food Science & Technology
Juan Wang, Yujia Xie, Yuanyuan Luan, Tingting Guo, Shanshan Xiao, Xingxing Zeng, Shaohui Zhang
Summary: The objective of this study was to isolate and identify intracellular bioactive peptides from mouse lymphocytes before and after lipopolysaccharide (LPS) stimulation. A total of 131 novel peptides were discovered, and their bioactivity and function were predicted. Two peptides with better inhibition activity were verified.
FOOD SCIENCE AND HUMAN WELLNESS
(2022)
Article
Medicine, General & Internal
Mingtong Xu, Kan Sun, Wenjie Xu, Chuan Wang, Dewen Yan, Shu Li, Li Cong, Yinzhen Pi, Weihong Song, Qingyuan Sun, Rijun Xiao, Weixia Peng, Jianping Wang, Hui Peng, Yawei Zhang, Peng Duan, Meiying Zhang, Jianying Liu, Qingmei Huang, Xuefeng Li, Yan Bao, Tianshu Zeng, Kun Wang, Li Qin, Chaoming Wu, Chunying Deng, Chenghu Huang, Shuang Yan, Wei Zhang, Meizi Li, Li Sun, Yanjun Wang, Hongmei Li, Guang Wang, Shuguang Pang, Xianling Zheng, Haifang Wang, Fujun Wang, Xiuhai Su, Yujin Ma, Wei Zhang, Ziling Li, Zuoling Xie, Ning Xu, Lin Ni, Li Zhang, Xiangqun Deng, Tianrong Pan, Qijuan Dong, Xiaohong Wu, Xingping Shen, Xin Zhang, Qijing Zou, Chengxia Jiang, Jue Xi, Jianhua Ma, Jingchao Sun, Li Yan
Summary: The study aimed to evaluate the efficacy and safety of a novel DPP-4 inhibitor, fotagliptin, in treatment-naive patients with T2DM. The results demonstrated that fotagliptin was non-inferior to alogliptin in improving glycemic control, with significantly more patients in the fotagliptin and alogliptin groups achieving HbA1c < 7.0% after 24 weeks of treatment.
Article
Public, Environmental & Occupational Health
Cheng-Yi Wang, Kuang-Ming Liao, Ya -Hui Wang, Kuang-Hung Chen, Shulin Chuang, Chia-Jung Liu, Chin-Chung Shu, Hao-Chien Wang
Summary: This study suggests that the use of DPP4i in patients with type 2 diabetes does not increase the risk of mycobacterial pulmonary infections.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2023)
Article
Endocrinology & Metabolism
Linong Ji, Jinmiao Lu, Leili Gao, Changjiang Ying, Jiao Sun, Jie Han, Wenhua Zhao, Yunming Gao, Kun Wang, Xin Zheng, Daosheng Xie, Juping Ding, Jiahong Zhao, Qiang Yu, Tong Wang
Summary: This study assessed the efficacy and safety of the dipeptidyl peptidase-4 inhibitor, cetagliptin, as monotherapy in Chinese patients with type 2 diabetes (T2D). The results showed that cetagliptin effectively reduced HbA1c levels, and the incidence of adverse events was similar to the placebo group. Therefore, cetagliptin monotherapy is effective and well tolerated in Chinese patients with T2D.
DIABETES OBESITY & METABOLISM
(2023)
Article
Nutrition & Dietetics
Paulina Keska, Joanna Stadnik
Summary: This study found that peptides extracted from dry-cured pork loins have inhibitory effects on dipeptidyl peptidase IV, and retain their biological activity during the digestive process. These peptides may have potential as functional food ingredients for preventing and treating type 2 diabetes mellitus. Certain peptide sequences show promise as natural food compounds for maintaining good health.
Article
Oncology
Tzu- Chen, Fu-Jen Lee, Wan-Lun Hsu, Yong-Chen Chen, Mingchih Chen
Summary: Hepatocellular carcinoma (HCC) was the sixth most common cancer and the third leading cause of cancer death worldwide in 2020. Chronic hepatitis B virus (HBV) infection and type 2 diabetes mellitus (T2DM) are important risk factors for HCC. This study found that the use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) significantly reduced the risk of developing HCC in T2DM patients with chronic HBV infection.
Article
Geriatrics & Gerontology
Andrew R. Zullo, Robert J. Smith, Roee Gutman, Bianca Kohler, Matthew S. Duprey, Sarah D. Berry, Medha N. Munshi, David D. Dore
Summary: This study found that among NH residents, individuals who initiated DPP4Is had a lower rate of severe hypoglycemic events compared to those who initiated SUs, with no significant differences in other severe adverse events and death rates.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Endocrinology & Metabolism
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim, Kwan Woo Lee
Summary: The study demonstrated a significant decrease in HbA1c levels after switching to teneligliptin from other DPP-4 inhibitors in patients with T2DM, with sustained improvement in glycemic control for up to 52 weeks. Additionally, improvements were observed in FPG levels and lipid parameters, with no significant safety concerns identified throughout the study period.
Article
Endocrinology & Metabolism
Linong Ji, Jinmiao Lu, Leili Gao, Xiaoguang Yan, Jifang Li, Zhifeng Cheng, Lili Zhang, Junhang Tian, Ping Li, Jie Bai, Daosheng Xie, Jiahong Zhao, Juping Ding, Qiang Yu, Tong Wang
Summary: This study aimed to evaluate the efficacy and safety of cetagliptin added to metformin in Chinese patients with type 2 diabetes. The results showed that the addition of cetagliptin was more effective in glycemic control and well tolerated compared to metformin monotherapy.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
B. R. Yang, S. H. Cha, K. E. Lee, J. W. Kim, J. Lee, K-H Shin
Summary: The study found that in patients with type 2 diabetes, DPP-IV inhibitors do not increase the risk of osteoporosis compared to sulfonylureas, while a weak association was found between thiazolidinediones and increased risk of osteoporosis.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Medicine, Research & Experimental
Kai-Chia Yeh, Teng-Kuang Yeh, Chung-Yu Huang, Chih-Bo Hu, Min-Hsien Wang, Yu-Wen Huang, Ling-Hui Chou, Hsuan-Hui Ho, Jen-Shin Song, Tsu Hsu, Weir-Torn Jiaang, Yu-Sheng Chao, Chiung-Tong Chen
Summary: DBPR108 is a novel DPP-4-selective inhibitor that has demonstrated potent in vivo pharmacological effects and good safety profiles in animals. By inhibiting DPP-4 activity, it increases active GLP-1 and insulin levels while improving glucose tolerability in animals.
Article
Endocrinology & Metabolism
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K. Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik
Summary: The extension study evaluated the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus. Results showed a significant reduction in HbA1c levels and overall safety and tolerability up to 52 weeks, highlighting the positive effects of gemigliptin in managing T2DM.
DIABETES & METABOLISM JOURNAL
(2021)
Review
Urology & Nephrology
Nuria Montero, Laia Oliveras, Maria Jose Soler, Josep Maria Cruzado
Summary: PTDM is a common issue after kidney transplantation, affecting 50% of high-risk recipients. KDIGO has updated guidelines for diabetes management in CKD, focusing on newer antidiabetic agents. Generating evidence is necessary to safely use these treatments and evaluate their potential cardiovascular and renal benefits in PTDM patients.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Multidisciplinary Sciences
Sanghwa Park, Jiseon Jeong, Yunna Woo, Yeo Jin Choi, Sooyoung Shin
Summary: This cohort study using Korean health insurance data found that DPP-4 inhibitors were not associated with an increased risk of infections in type 2 diabetes patients receiving insulin treatment, while SGLT-2 inhibitors were found to be associated with a higher risk of genital infections. No increased risk of urinary tract infections was observed with SGLT-2 inhibitors compared to metformin.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Karel Smetana, Lukas Lacina, Pavol Szabo, Barbora Dvorankova, Prokop Broz, Aleksi Sedo
ANTICANCER RESEARCH
(2016)
Review
Gastroenterology & Hepatology
Premysl Fric, Jan Skrha, Aleksi Sedo, Tomas Zima, Petr Busek, Klara Kmochova, Martin Laclav, Bohus Bunganic, Svatopluk Solar, Petr Hrabal, Frantisek Belina, Pavel Zaruba, Pavel Skrha, Miroslav Zavoral
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2016)
Article
Plant Sciences
Barbora Dvorankova, Pavol Szabo, Ondrej Kodet, Hynek Strnad, Michal Kolar, Lukas Lacina, Eliska Krejci, Ondrej Nanka, Aleksi Sedo, Karel Smetana
Review
Gastroenterology & Hepatology
Premysl Fric, Aleksi Sedo, Jan Skrha, Petr Busek, Martin Laclav, Pavel Skrha, Miroslav Zavoral
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2017)
Review
Gastroenterology & Hepatology
Premysl Fric, Jan Skrha, Aleksi Sedo, Petr Busek, Martin Laclav, Bohus Bunganic, Miroslav Zavoral
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2017)
Article
Chemistry, Medicinal
Petra Dvorakova, Petr Busek, Tomas Knedlik, Jiri Schimer, Tomas Etrych, Libor Kostka, Lucie Stollinova Sromova, Vladimir Subr, Pavel Sacha, Aleksi Sedo, Jan Konvalinka
JOURNAL OF MEDICINAL CHEMISTRY
(2017)
Article
Biochemistry & Molecular Biology
Petr Busek, Rosana Mateu, Michal Zubal, Lenka Kotackova, Aleksi Sedo
FRONTIERS IN BIOSCIENCE-LANDMARK
(2018)
Article
Cell Biology
Njainday Pulo Jobe, Veronika Zivicova, Alzbeta Mifkova, Daniel Rosel, Barbora Dvorankova, Ondrej Kodet, Hynek Strnad, Michal Kolar, Aleksi Sedo, Karel Smetana, Karolina Strnadova, Jan Brabek, Lukas Lacina
HISTOCHEMISTRY AND CELL BIOLOGY
(2018)
Article
Multidisciplinary Sciences
Jiri Sana, Petr Busek, Pavel Fadrus, Andrej Besse, Lenka Radova, Marek Vecera, Stefan Reguli, Lucie Stollinova Sromova, Marek Hilser, Radim Lipina, Radek Lakomy, Leos Kren, Martin Smrcka, Aleksi Sedo, Ondrej Slaby
SCIENTIFIC REPORTS
(2018)
Review
Biochemistry & Molecular Biology
Adela Simkova, Petr Busek, Aleksi Sedo, Jan Konvalinka
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
(2020)
Article
Biochemistry & Molecular Biology
Evzen Krepela, Zdislava Vanickova, Petr Hrabal, Michal Zubal, Barbora Chmielova, Eva Balaziova, Petr Vymola, Ivana Matrasova, Petr Busek, Aleksi Sedo
Summary: The study demonstrates a significant positive correlation between TGFbeta and FAP in glioblastomas, with TGFbeta-1 promoting FAP expression in various cell types present in the glioblastoma microenvironment. The effect is mediated by TGFbeta-1 secreted by glioma cells and involves activation of FAP gene transcription.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Eva Balaziova, Petr Vymola, Petr Hrabal, Rosana Mateu, Michal Zubal, Robert Tomas, David Netuka, Filip Kramar, Zuzana Zemanova, Karla Svobodova, Marek Brabec, Aleksi Sedo, Petr Busek
Summary: The study identified a subpopulation of FAP(+) mesenchymal cells in the perivascular niche in glioblastoma that may contribute to tumor progression by promoting angiogenesis and supporting dissemination of transformed cells into the surrounding tissue. These cells, which express proangiogenic factors, play a role in promoting angiogenesis and glioma cell migration and growth through paracrine communication, potentially contributing to the advancement of glioblastoma.
Review
Oncology
Petr Busek, Jonathan S. Duke-Cohan, Aleksi Sedo
Summary: There is growing interest in the effects of antidiabetic agents on cancer risk, progression, and treatment. Dipeptidyl peptidase-IV (DPP-IV) inhibitors, currently used in patients with type 2 diabetes, have been shown to have potential applications in cancer prevention and treatment. However, there are potential risks associated with DPP-IV inhibition in cancer, and further research is needed to fully understand the impact of these medications on cancer.
Article
Engineering, Biomedical
Ivana Matrasova, Petr Busek, Eva Balaziova, Aleksi Sedo
BIOMEDICAL PAPERS-OLOMOUC
(2017)
Article
Biochemistry & Molecular Biology
Evzen Krepela, Petr Busek, Marek Hilser, Zdislava Vanickova, Aleksi Sedo
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2017)